2010 - 2012

Categories:History
Author:
Origin:
Time of issue:2012-03-09
Views:0

(Summary description)<h3 style="font-size:20px; font-weight:bold;">Winning the titles of
</h3>
◆ Leading Talent of Suzhou Industrial Park.
◆ Leading Innovative and Entrepreneurial Talent of Suzhou.

2010 - 2012

(Summary description)<h3 style="font-size:20px; font-weight:bold;">Winning the titles of
</h3>
◆ Leading Talent of Suzhou Industrial Park.
◆ Leading Innovative and Entrepreneurial Talent of Suzhou.

Categories:History
Author:
Origin:
Time of issue:2012-03-09
Views:0

Company Startup

Previous: 2012 - 2013

Next: /

Previous: 2012 - 2013

Next: /

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.

2023-02-02

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.

2022-10-17